-
Product Insights
NewAcromegaly – Drugs In Development, 2024
Empower your strategies with our Acromegaly – Drugs In Development, 2024 report and make more profitable business decisions. Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea. Treatment includes surgery, dopamine agonists, and growth hormone antagonists. The Acromegaly drugs in development market research report provide comprehensive information on...
-
Product Insights
NewLeiomyoma – Drugs In Development, 2024
Empower your strategies with our Leiomyoma – Drugs In Development, 2024 report and make more profitable business decisions. A leiomyoma, also known as a fibroid, is a benign smooth muscle tumor that very rarely becomes cancer. They can occur in any organ, but the most common forms occur in the uterus, small bowel, and the esophagus. It commonly affects individuals between menarche and menopause. The Leiomyoma drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewAcute Heart Failure – Drugs In Development, 2024
Empower your strategies with our Acute Heart Failure – Drugs In Development, 2024 report and make more profitable business decisions. Acute heart failure (AHF) is a critical medical condition characterized by a sudden onset or rapid worsening of symptoms related to the heart's inability to pump blood effectively. This leads to insufficient oxygen delivery to tissues and organs. AHF can manifest as either new-onset heart failure or exacerbation of chronic heart failure. Common symptoms include shortness of breath, fatigue, and fluid...
-
Product Insights
NewUterine Leiomyoma (Uterine Fibroids) – Drugs In Development, 2024
Empower your strategies with our Uterine Leiomyoma (Uterine Fibroids) – Drugs In Development, 2024 report and make more profitable business decisions. Uterine leiomyoma, also known as uterine fibroids, are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods (seven days or...
-
Product Insights
NewAdenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024
Empower your strategies with our Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024 report and make more profitable business decisions. Adenoid cystic carcinoma (ACC) is a rare and aggressive type of cancer that originates from glandular tissues. It can occur in various parts of the body, but it is most found in the salivary glands of the head and neck region. ACC is characterized by a MYB oncogene activation and a tendency to invade nerves and metastasize to distant organs....
-
Product Insights
NewGastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood...
-
Product Insights
NewMesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely,...
-
Product Insights
NewMesenchymal Tumor – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors are tumors developing from mesenchymal tissues. These tissues are made of cells including fibroblasts, nerve cells, blood vessel cells, muscle cells, and others. Benign soft tissue tumors are common in humans, but cancerous mesenchymal tumors are rare. Many tumors can originate from various cells, and the treatment mainly depends on the tumor's type, severity, and aggressiveness. These are soft tissue...